Browsing Tag
Dark Blue Therapeutics Ltd.
1 post
Amgen (NASDAQ: AMGN) bets on protein degradation with Dark Blue Therapeutics acquisition
Amgen acquires Dark Blue Therapeutics for up to $840M, expanding into MLLT1/3-targeted AML therapies. Find out what this means for oncology innovation today.